VAXNEUVANCE should be considered for your at-risk populations

At year-end 2022 in the US and 6 dependent areas, the rate of children aged <13 years living with diagnosed HIV infection was 2.2/100,000 (~1,126 total cases)^2,a

During 2016–2020 in the US, the rate of SCD was approximately 4.8/10,000 live births (3,305 total cases)^3,b

In 2021–2022, 1.0% of US parents of children with asthma rated the severity of asthma in their children aged ≤5 years as moderate/severe^4,c,d

^aData for the year 2022 are preliminary and based on deaths reported to CDC as of December 2023. Data are based on address of residence as of December 31, 2022 (ie, most recent known address).^2
bThe CDC-funded Sickle Cell Data Collection program included 11 state-level surveillance programs from the southern, midwestern, and western United States, and collects and analyzes state newborn screening records.^3
cBased on data collected in the National Survey of Children’s Health (NSCH), which is fielded annually by the US Census Bureau. Randomly sampled households were contacted by mail to identify those with one or more children under 18 years old. In each household, one child was randomly selected to be the subject of the survey, which oversampled children with special health care needs and children 0–5 years of age. Asthma prevalence is sourced from the 2021–2022 combined dataset.^4,8
dVAXNEUVANCE Study 12 (Protocol 024) included children with a medical history of asthma (VAXNEUVANCE: n=10; PCV13: n=10).^9
eBased on a US analysis of MarketScan Commercial Claims and Medicare data from August 1, 2012, through July 31, 2017, done to explore the prevalence of immunosuppressive conditions. Enrollees with symptomatic HIV/AIDS or sickle cell disease were among those considered immunosuppressed.⁷

VAXNEUVANCE is the only CDC recommended PCV with clinical studies that was specifically designed to evaluate immune responses in special populations with a need for pneumococcal disease prevention based on their diagnosed risk condition, such as people living with HIV or SCD.¹⁰

^fPediatric populations with risk conditions were preterm infants, children living with HIV or SCD (immunocompromising diseases), or children who had received an allo-HSCT (an immunocompromising condition): preterm infants, <37 weeks gestation at birth; children living with HIV, 6–17 years of age; children living with SCD, 5–17 years of age; and recipients of allo-HSCT, 3–17 years of age.¹¹

Choose the robust immunogenicity of VAXNEUVANCE for your appropriate pediatric patients—including those with immunocompromising conditions.

AIDS, acquired immunodeficiency syndrome; allo-HSCT, allogeneic hematopoietic stem cell transplant; CDC, Centers for Disease Control and Prevention; GMC, geometric mean concentration (mcg/mL); GMT, geometric mean titer; GVHD, graft-versus-host disease; HIV, human immunodeficiency virus; IgG, Immunoglobulin G; IPD, invasive pneumococcal disease; OPA, opsonophagocytic activity; PCV, pneumococcal conjugate vaccine; PCV13, 13-valent pneumococcal conjugate vaccine; PPSV23, 23-valent pneumococcal polysaccharide vaccine; RNA, ribonucleic acid; SCD, sickle cell disease.

References: